Skip to content
by Legal Desire
16 August 2024

Latham & Watkins Advises on ANI Pharmaceuticals’ Upsized US$316.25 Million Convertible Senior Notes Offering

Advising firms

Deal team

24 lawyers named
LawyerFirmSeniorityPracticeOffice
Greg Rodgers Lead Latham & Watkins LLP Partner capital markets New York/Los Angeles
Arash Aminian Baghai Lead Latham & Watkins LLP Partner capital markets Los Angeles
Brent Epstein Lead Latham & Watkins LLP Partner capital markets Century City
Andrew Bentz Latham & Watkins LLP Associate capital markets Not stated
Eric Finkelberg Latham & Watkins LLP Associate capital markets Not stated
Dylan Shamoon Latham & Watkins LLP Associate capital markets Not stated
Reza Mojtabaee-Zamani Latham & Watkins LLP Partner equity derivatives New York
Kevin Zhang Latham & Watkins LLP Associate equity derivatives Not stated
Elena Romanova Latham & Watkins LLP Partner tax New York
Aaron Bernstein Latham & Watkins LLP Partner tax New York
Tessa Young Latham & Watkins LLP Associate tax Not stated
James Aldred Latham & Watkins LLP Associate tax Not stated
Aron Potash Latham & Watkins LLP Partner environmental Los Angeles
Qingyi Pan Latham & Watkins LLP Associate environmental Not stated
Chad Jennings Latham & Watkins LLP Counsel FDA Washington, D.C.
Carolyne Hathaway Latham & Watkins LLP Of counsel FDA Washington, D.C.
Trevor Thompson Latham & Watkins LLP Associate FDA Not stated
Betty Pang Latham & Watkins LLP Partner healthcare regulatory Bay Area
Jeffrey Tochner Latham & Watkins LLP Partner intellectual property New York
Pelin Serpin Latham & Watkins LLP Associate intellectual property Not stated
Heather Deixler Latham & Watkins LLP Partner cybersecurity Bay Area
Mitch Bennett Latham & Watkins LLP Associate cybersecurity Not stated
Benjamin Rosemergy Latham & Watkins LLP Partner compensation and benefits Chicago
Joseph Benedetto Latham & Watkins LLP Associate compensation and benefits Not stated

Stated terms

Stated value
USD 316m (US$316.25 million)
What the figure measures
Issue size
Client
ANI Pharmaceuticals, Inc.Issuer
Counterparties
initial purchasers (Investor)